Literature DB >> 2585556

Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients.

R L Reed1, A H Wu, P Miller-Crotchett, J Crotchett, R P Fischer.   

Abstract

An assessment of the dosage regimens prescribed for potentially nephrotoxic antibiotics (amikacin, gentamicin, tobramycin, and vancomycin) was undertaken on surgical intensive care unit patients. In 166 patients, 224 series of blood antibiotic level determinations were obtained. Using individualized pharmacokinetic determinations, the regimens were revised as necessary to provide optimal blood levels. Because of variable volumes of distribution and elimination rates, dosing according to standard clinical guidelines produced significantly lower peaks than did pharmacokinetically determined regimens for gentamicin (p less than 0.005), tobramycin (p less than 0.0001), and vancomycin (p less than 0.05). Importantly, fewer patients achieved therapeutic levels with the original regimens than with the revised regimens for gentamicin (9% vs. 91%, p less than 0.0005), tobramycin (27% vs. 92%, p less than 0.0001), and vancomycin (30% vs. 69%, p less than 0.0001). Individualized pharmacokinetic analysis of potentially nephrotoxic antibiotics in critically ill patients is essential if therapeutic, non-toxic levels are to be maintained.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2585556     DOI: 10.1097/00005373-198911000-00002

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  13 in total

1.  Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.

Authors:  J Debord; J C Voultoury; G Lachatre; C Gay; J P Favereau; R Gay
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.

Authors:  K Vandewoude; D Vogelaers; J Decruyenaere; P Jaqmin; K De Beule; A Van Peer; R Woestenborghs; K Groen; F Colardyn
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 3.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 5.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 6.  Glycopeptides and nephrotoxicity.

Authors:  A W Chow; R M Azar
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

7.  Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina.

Authors:  Muhammad Jamshaid; Samia Yousuf; Nadeem Irfan Bukhari; Amir Ali Rizvi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

Review 8.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

9.  Pharmacokinetics of meropenem in patients with intra-abdominal infections.

Authors:  A Bedikian; M P Okamoto; R K Nakahiro; J Farino; P N Heseltine; M D Appleman; A E Yellin; T V Berne; M A Gill
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

Review 10.  Aminoglycosides--50 years on.

Authors:  E J Begg; M L Barclay
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.